Blog
RSS FeedPosted by Michael Wonder on 29 Nov 2023
eFFECTOR receives US FDA fast track designation for zotatifin in combination with fulvestrant and abemaciclib for treatment of ER positive/HER2 negative advanced metastatic breast cancer
28 November 2023 - Designation is for second or third-line treatment of patients with disease progression following treatment with endocrine therapy ...
Posted by Michael Wonder on 09 Jun 2023
PHARMAC breast cancer cost saving proposal welcome but ignores patients facing “dead-end”
8 June 2023 - Breast Cancer Foundation NZ is urging PHARMAC to widen access to an already funded treatment for ...
Posted by Michael Wonder on 05 Mar 2023
Catherine has stage four breast cancer, but she can't access a new treatment in Australia
3 March 2023 - In 2015, twelve weeks after the birth of her second daughter, Catherine King was diagnosed with late-stage ...
Posted by Michael Wonder on 28 Nov 2022
Kintara Therapeutics granted fast track designation from FDA for REM-001 for cutaneous metastatic breast cancer
28 November 2022 - Kintara Therapeutics today announced that the US FDA has granted fast track designation to Kintara's REM-001 ...
Posted by Michael Wonder on 21 Jan 2018
A tale of 2 friends with breast cancer; 1 has coverage for costly drug, the other forced to pay
20 January 2018 - Two women say their cases challenge commonly held belief that B.C. is the gold standard for cancer ...
Posted by Michael Wonder on 07 Jan 2018
Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers
4 January 2018 - This study evaluated the cost-effectiveness of BRCA testing in Australian women with breast cancer, and cascade ...
Posted by Michael Wonder on 01 Oct 2016
Breast cancer drug tamoxifen listed on Pharmaceutical Benefits Scheme
1 October 2016 - More Australian women will have access to a preventative breast cancer medicine that has been listed on ...
Posted by Michael Wonder on 09 May 2016
Updated treatment algorithm for the treatment of HER2+ metastatic breast cancer
1 May 2016 - The PBAC treatment algorithm for anti-HER2 therapies for treating metastatic breast cancer has been updated to reflect ...